JDC-JSC’s Royalty Pharma RPRX Stock Holding History

JDC-JSC’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	$358K	Buy	+8,500	New	+$365K	1.72%	20

Other funds holding RPRX

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

HMC

Harvard Management Company Boston, Massachusetts $1.82B AUM 26.23% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JDC-JSC's RPRX Position: Q3 2020 in Review

JDC-JSC opened a new position in Royalty Pharma (RPRX) in Q3 2020: 8,500 shares worth $358K. The stake represents 1.72% of the portfolio and ranks #20 among its holdings.

134 funds tracked by Wall St. Rank hold RPRX as of Q3 2020.

JDC-JSC held 8,500 shares of Royalty Pharma worth $358K as of Q3 2020.
Royalty Pharma was a new JDC-JSC position in Q3 2020.
Royalty Pharma made up 1.72% of JDC-JSC's portfolio in Q3 2020, its #20 holding.
134 funds tracked by Wall St. Rank held Royalty Pharma as of Q3 2020.

Based on JDC-JSC's 13F filing for Q3 2020, filed 3 Nov 2020.